SAN FRANCISCO, May 18, 2017 /PRNewswire/ -- Nektar
Therapeutics (Nasdaq: NKTR) today announced its presence at the
upcoming 2017 American Society of Clinical Oncology (ASCO) Annual
Meeting, where it will share updated data from clinical studies of
NKTR-214. ASCO will take place June
2-6, 2017 in Chicago.
NKTR-214 is an investigational immuno-stimulatory therapy
designed to expand specific cancer-fighting CD8+ effector T cells
and natural killer (NK) cells directly in the tumor
micro-environment and increase expression of PD-1 on these immune
cells.
"We look forward to providing updates on NKTR-214, including the
first data from the PIVOT trial evaluating NKTR-214 in combination
with nivolumab, as well as updated data from the monotherapy trial
of NKTR-214, including I-O naïve RCC patients who received
sequential checkpoint therapy following treatment with NKTR-214,"
said Mary Tagliaferri, M.D., Senior
Vice President of Clinical Development at Nektar Therapeutics.
"NKTR-214's unique mechanism which selectively increases
tumor-killing TILs, combined with its favorable safety profile and
clinical activity, support our combination trials of NKTR-214 with
existing checkpoint inhibitors such as nivolumab and atezolizumab,
as well as other immuno-oncology mechanisms in development."
NKTR-214 targets CD122 specific receptors found on the surface
of cancer-fighting immune cells in order to stimulate their
proliferation. In clinical and preclinical studies, treatment with
NKTR-214 resulted in expansion of these cells and mobilization into
the tumor micro-environment.1,2,3 NKTR-214 has an
antibody-like dosing regimen similar to the existing checkpoint
inhibitor class of approved medicines.
The abstracts published in advance of the ASCO meeting which
were made available yesterday on the ASCO website at www.asco.org
include preliminary data only as of February
7, 2017. Updated and additional patient data from
these trials will be presented at ASCO.
Abstract 2545/Poster 37: "Effect of a novel IL-2 cytokine
immune agonist (NKTR-214) on proliferating CD8+T cells and PD-1
expression on immune cells in the tumor microenvironment in
patients with prior checkpoint therapy."
Presenter: Chantale Bernatchez,
Ph.D., The University of Texas MD
Anderson Cancer Center
Poster Session: Developmental Therapeutics—Clinical Pharmacology
and Experimental Therapeutics
Date and Time: Monday, June 5, 2017 -
8:00 a.m. - 11:30 a.m. CDT
Location: Hall A
Abstract e14040: "A phase 1/2 study of a novel IL-2 cytokine,
NKTR-214, and nivolumab in patients with select locally advanced or
metastatic solid tumors." Diab, A., et al.
Publication abstract to be included online in the 2017 ASCO
Annual Meeting Proceedings, a Journal of Clinical Oncology
supplement.
Nektar will host an analyst and investor event with clinical
investigators on Saturday, June 3,
2017 at 6:00 pm CDT in
Chicago, IL during the 2017
American Society of Clinical Oncology (ASCO) Meeting.
Presenters will include lead investigators from the NKTR-214
trial: Dr. Adi Diab, Assistant
Professor, Melanoma Medical Oncology at the University of Texas MD Anderson Cancer Center, Dr.
Nizar Tannir, Professor,
Genitourinary Medical Oncology at the University of Texas MD Anderson Cancer Center and
Dr. Michael Hurwitz, Assistant
Professor of Medicine (Medical Oncology) at Yale Cancer Center.
To register for the webcast of the event please visit:
http://edge.media-server.com/m/p/guf8mqwk.
Seating is limited to attend the event in person, please contact
jsievers@nektar.com for more information.
About Nektar
Nektar Therapeutics is a research-based
biopharmaceutical company whose mission is to discover and develop
innovative medicines to address the unmet medical needs of
patients. Our R&D pipeline of new investigational medicines
includes treatments for cancer, auto-immune disease and chronic
pain. We leverage Nektar's proprietary and proven chemistry
platform in the discovery and design of our new therapeutic
candidates. Nektar is headquartered in San Francisco, California, with additional
operations in Huntsville, Alabama
and Hyderabad, India. Further
information about the company and its drug development programs and
capabilities may be found online at http://www.nektar.com.
Cautionary Note Regarding Forward-Looking
Statements
This press release contains forward-looking
statements which can be identified by words such as: "anticipate,"
"intend," "plan," "expect," "believe," "should," "may," "will" and
similar references to future periods. Examples of forward-looking
statements include, among others, statements we make regarding the
therapeutic potential of NKTR-214, the therapeutic potential of
NKTR-214 in combination with other therapeutic agents, and the
potential of our technology and drug candidates in our research and
development pipeline. Forward-looking statements are neither
historical facts nor assurances of future performance. Instead,
they are based only on our current beliefs, expectations and
assumptions regarding the future of our business, future plans and
strategies, anticipated events and trends, the economy and other
future conditions. Because forward-looking statements relate to the
future, they are subject to inherent uncertainties, risks and
changes in circumstances that are difficult to predict and many of
which are outside of our control. Our actual results may differ
materially from those indicated in the forward-looking statements.
Therefore, you should not rely on any of these forward-looking
statements. Important factors that could cause our actual results
to differ materially from those indicated in the forward-looking
statements include, among others: (i) our statements regarding the
therapeutic potential of NKTR-214 are based on pre-clinical and
clinical findings and observations; (ii) NKTR-214 is in early-stage
clinical development and there are substantial risks that can
unexpectedly occur for numerous reasons including negative safety
and efficacy findings in the ongoing Phase 1/2 clinical studies
notwithstanding positive findings in preclinical and clinical
studies; (iii) data reported from ongoing clinical trials is
necessarily interim data only and the final results will change
based on continuing observations from patients that currently
remain enrolled in the trials and/or new observations from patients
enrolling in the trials; (iv) the length of time to complete
ongoing clinical trials and the availability of clinical data may
be delayed or unsuccessful due to regulatory delays, slower than
anticipated patient enrollment, manufacturing challenges, changing
standards of care, and other reasons; (v) scientific discovery of
new medical breakthroughs is an inherently uncertain process and
the future success of applying our technology platform to potential
new drug candidates (such as NKTR-214) is therefore highly
uncertain and unpredictable; (vi) patents may not issue from our
patent applications for our drug candidates including NKTR-214,
patents that have issued may not be enforceable, or additional
intellectual property licenses from third parties may be required;
and (vii) certain other important risks and uncertainties set forth
in our Quarterly Report on Form 10-Q filed with the Securities and
Exchange Commission on May 10, 2017. Any forward-looking
statement made by us in this press release is based only on
information currently available to us and speaks only as of the
date on which it is made. We undertake no obligation to update any
forward-looking statement, whether written or oral, that may be
made from time to time, whether as a result of new information,
future developments or otherwise.
Contact:
For Investors:
Jennifer Ruddock of Nektar
Therapeutics
415-482-5585
For Media:
Dan Budwick
1AB Media
973-271-6085
- Charych, D., et al., Cancer Res. 2013;73(8 Suppl):Abstract nr
482 and Data on file.
- Hoch U., et al., AACR; Mol Cancer Ther. 2013;12(11
Suppl):Abstract nr B296.
- Diab, A., et al., SITC 2016.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/nektar-therapeutics-announces-data-presentations-at-asco-2017-300459951.html
SOURCE Nektar Therapeutics